Navigation Links
Significant in Medical Technology

New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF

AMSTERDAM, The Netherlands, June 30 /PRNewswire/ -- - "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment" New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHR...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

- Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific Sessions Expand on Previously Announced Positive Top-Line Results - NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

First-Ever Trial to Evaluate Whether Olmesartan Medoxomil Prevents Onset of Early Kidney Disease in Type 2 Diabetes Patients SAN FRANCISCO, May 8 /PRNewswire/ -- Blinded one-year blood pressure (BP) reduction data from the ongoing landmark study ROADMAP ( R andomized O lmesartan A nd D ...

China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit

HARBIN, China, May 4 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the R...

Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer's Trabecular Metal(TM) Technology

10-Year Study Highlights Trabecular Metal Technology's Clinical Success Over Traditional Metal Implants WARSAW, Ind., Feb. 25 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ZMH), a leader in the orthopaedic industry, today announced that data from an independent 10-ye...

Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix

Primate trials validate efficacy of the process THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has successfully completed the initial primate trials validating the efficacy of the proprietary bone growth regeneration UCB-1 (NELL-1) protein in spina...

Oridion Announces Significant Medical Studies Presented at STA

JERUSALEM and NEEDHAM, Massachusetts, February 2 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN). During the recent annual meeting of the Society for Technology in Anesthesia (STA) San Antonio, Texas, major new findings from numerous medical research projects demonst...

Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline

CAMBRIDGE, England, January 12 /PRNewswire/ -- Biotica Technology Limited, a privately-held biotechnology company, announces a significant Collaboration and License Agreement with GlaxoSmithKline to discover, develop and commercialise novel erythromycin-based macrolides in inflammatory disease...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

US Oncology Affiliated Physicians Participate in ASH Conference SAN FRANCISCO, Dec. 8 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network will present findings from a randomized, multicenter Phase III trial that compared FCR and PCR in patients wit...

PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients

- PTC124 Highlighted in Multiple Presentations at North American Cystic Fibrosis Conference - SOUTH PLAINFIELD, N.J. and ORLANDO, Fla., Oct. 24 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with...

Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period

Results of FLEXX Trial Presented at the Osteoarthritis Research Society International's 2008 World Congress PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Ferring Pharmaceuticals Inc. recently presented results from the FLEXX Trial of Osteoarthritis of the Knee, showing that EUFLEXXA(R) (1% sodium...

Concord Grape Juice Has No Significant Impact on Body Weight

Recent study revealed that drinking polyphenol-rich 100% Concord grape juice was not associated with changes in appetite, energy intake or body weight CONCORD, Mass., Oct. 6 /PRNewswire/ -- Regular consumption of 100% polyphenol-rich Concord grape juice did not cause significant weight gain,...

Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence

Study Shows near 80% Improvement In Outcomes PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny General Hospital (AGH) in Pittsburgh today will report to the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a newer, minimally inv...

Bionovo's MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes

EMERYVILLE, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) today announced that its lead drug candidate, MF101, for menopausal hot flashes, showed improved sleep quality for women in a Phase 2 study completed earlier this year. The Company previously announced that t...

Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis

Clinical Data Presented at American Academy of Dermatology Summer Meeting PRINCETON, N.J., July 31 /PRNewswire/ -- NeoStrata today announced findings from an ongoing 12-week study that demonstrates benefits of a novel topically applied LCD (coal tar) solution (Psorent(TM)) versus calcipotriol c...

The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer

- Nexavar is First Approved Systemic Therapy to Treat the Disease - WAYNE, N.J. and EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that The New England Journal of Medicine published results ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

EORTC 18991 Phase III Study Results Published in The Lancet KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough (NYSE: SGP ) and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant and sus...

Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine

GAITHERSBURG, Md. and VIENNA, Austria, June 11 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) today announced the publication of data from the company's positive Phase II field study of its travelers' diarrhea vaccine in The Lancet. The study, which analyzed data from 170 travele...

Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies

Data from five pivotal phase 3 studies presented at the American Diabetes Association 68th Scientific Sessions SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association (ADA) 68th Scie...

Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer

- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1) - Findings may allow clinicians to improve standard of care for premenopausal women diagn...

New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk

- AtCor Medical's SphygmoCor system plays key role in discovery ITASCA, Ill. and SYDNEY, Australia, May 28 /PRNewswire-FirstCall/ -- A new study of more than 10,000 patients, conducted by the Universities of Cambridge and Cardiff in the United Kingdom using AtCor Medical Holdings Limited's...

TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

SAN MARINO, Calif., May 22 /PRNewswire/ -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

First Presentation of Full Data Set from the TRIUMPH-1 Trial of Inhaled Treprostinil SILVER SPRING, Md., May 21 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data from s...

Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients

- Study shows significantly improved bronchodilation and symptom control with combination therapy - NAPA, Calif., May 20 /PRNewswire/ -- A newly published study presents data demonstrating that patients with Chronic Obstructive Pulmonary Disease (COPD), including emphysem...

Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone

-- Clinical trial data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution presented at International ATS Conference -- NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant ...

Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

CHICAGO, May 20 /PRNewswire/ -- GlaxoSmithKline and Synta Pharmaceuticals Corp. (Nasdaq: SNTA ) today announced positive Phase II clinical data for elesclomol (formerly STA-4783), an investigational agent currently in development for metastatic melanoma. A retrospective analysis showed that s...

Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients

Single Molecule with Dual Mechanism May Offer Novel Approach to Blood Pressure Management NEW ORLEANS, May 16 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today tha...

Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions

Patch Formulation May Provide New Option for Clinicians Concerned About Systemic Exposure When Using an Oral NSAID TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a leading global specialty pharmaceutical company, announced today that two studies to be p...

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investiga...

Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care

NEWPORT NEWS, Va., April 29 /PRNewswire/ -- Recently published data in The American Journal of Surgery by a group of surgeons from Legacy Good Samaritan Hospital in Portland, Oregon, demonstrates the value of using Breast-Specific Gamma Imaging (BSGI) for the clinical management of breast canc...

BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies

- BiPar Sciences Presents First Peer-Reviewed Preclinical Results for BSI-201 at 2008 AACR Annual Meeting - SAN DIEGO, April 14 /PRNewswire/ -- BiPar Sciences, Inc. today announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PAR...

Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics

Presented at Miami Breast Cancer Conference, study demonstrates BSGI is both patient and cost effective. NEWPORT NEWS, Va., March 6 /PRNewswire/ -- A recent study performed by Dr. Margaret Bertrand, Director of Breast Imaging at Solis Bertrand Breast Center in Greensboro, No...

On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments

ANN ARBOR, Mich., Feb. 19 /PRNewswire/ -- Compendia Bioscience, Inc. today announced results of a second productive year, including a renewed and expanding commitment from all major customers and the addition of several "Top 20" oncology drug companies to its customer roster. The new customers...

Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets

BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has achieved significant milestones in the development of isosorbide m...

Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study

Achieves Statistically Significant ACR20, ACR50 & ACR70 Results SOUTH SAN FRANCICSO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that its oral syk kinase inhibitor, R788 (tamatinib fosdium), has demonstrated statistically significa...

PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity

Data Presented at the American Society of Hematology (ASH) Annual Meeting Publication Number: 840 CHESHIRE, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patien...

Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration

Published Results Also Show Potentially Differentiating Pharmacokinetic Profile of Prodrug Stimulant PHILADELPHIA, Nov. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced that Biologic...

Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show

NEW YORK, Nov. 8 /PRNewswire/ -- Total daily dosages of milnacipran 100 mg and 200 mg demonstrated statistically significant and clinically meaningful improvements in both pain and other core symptoms associated with fibromyalgia syndrome (FMS), according to Phase III data presented this week ...

Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms

- New data from TOWARD study highlight significant improvements in RA symptoms achieved with the unique inhibiting action of ACTEMRA that specifically targets interleukin-6 receptors - NUTLEY, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Data from two pivotal multinational Phase III cl...

Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease

LEXINGTON, Mass., Nov. 7 /PRNewswire/ -- ActivBiotics, Inc. today announced the results of its PROVIDENCE-1 clinical trial, which evaluated the effect of rifalazil in the treatment of intermittent claudication, associated with peripheral arterial disease (PAD). The results demonstrated that tr...
Other Tags
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan Service ... agreed to a partnership with Gabriel Health Institute, ... fastest growing Certified Nursing Assistant preparatory schools. ...  an exclusive member of Binary,s LiveScan service provider,s ... will improve its service capabilities by widening ...
(Date:8/21/2014)... AWI geologist Juliane Mller the Fram Strait is a key ... of this passage between Greenland and Svalbard warm Atlantic water ... the west side cold Arctic water masses and sea ice ... Atlantic. A considerable portion of the Atlantic water cools here ... layers. The circulation of the water caused in this manner ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
(Date:8/22/2014)... UWDress.com, a leading online supplier of wedding dresses and women’s ... empire bridesmaid dresses to its product line. In addition ... these high quality items. All of them are now available ... , The company’s new items can definitely add beauty ... website. It is true that all its products are more ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Japantown ... offering a new teeth whitening technique. Air polishing is ... cleaning appointments. , Dark teeth can be caused by ... categories: external stains and internal stains. External stains include ... can be caused by certain medications, such as tetracycline, ...
(Date:8/22/2014)... Amy Norton HealthDay Reporter ... growing number of Americans on work disability chronically use ... Researchers found that between 2007 and 2011, about 44 ... were prescribed narcotic painkillers each year. And the percentage ... 2007 to 23 percent in 2011. Experts ...
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... that uses university-proven research to show people how they can ... lean muscle in only a matter of weeks has caught ... , “Ben Pakulski is one of the most well-known bodybuilders ... get the body he has today, that in itself is ...
Breaking Medicine News(10 mins):Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Japantown Dental Introduces Air Polishing 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
Other Contents